In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan.


Zoledronate, also known as zoledronic acid, is classified as a bisphosphonate and, more broadly, an antiresorptive medication. Zoledronate is approved by the US Food and Drug Administration (FDA) for various indications, including the prevention and treatment of osteoporosis in males and postmenopausal females, glucocorticoid-induced osteoporosis, Paget disease of bone, hypercalcemia of malignancy, multiple myeloma, and solid tumor bone metastases. Zoledronate is administered intravenously and is commonly prescribed and indicated to treat various metabolic bone disorders, including both malignant and benign diseases. As zoledronate is administered intravenously, it can be utilized in patients with an intolerance or contraindication to oral bisphosphonates.

Publication types

  • Study Guide